Clinical Trials Logo
  1. Home
  2. Salivary Gland Cancer
  3. NCT05694819

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Salivary Gland Cancer Clinical Trial

Official title:
Phase II Study of Darolutamide (ODM-201) in Patients With Androgen Receptor-positive Salivary Gland Carcinoma (Discovary Study)

Clinical Trial Summary

This study is an open-label phase 2 study to evaluate the safety and efficacy of Darolutamide monotherapy in patients with androgen receptor-positive salivary gland carcinoma. Moreover, this study will evaluate the safety and efficacy of Darolutamide and Goserelin combination in patients with androgen receptor-positive salivary gland carcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05694819
Study type Interventional
Source National Cancer Center Hospital East
Contact
Status Active, not recruiting
Phase Phase 2
Start date April 17, 2020
Completion date February 2026
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03729297 - Cabozantinib in Advanced Salivary Gland Cancer Patients Phase 2
Active, not recruiting NCT01969578 - Androgen Deprivation Therapy in Advanced Salivary Gland Cancer Phase 2
Completed NCT01703455 - Activity of Sorafenib in Salivary Gland Cancer Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Active, not recruiting NCT05010629 - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma Phase 2
Active, not recruiting NCT03781986 - APG-115 in Salivary Gland Cancer Trial Phase 1/Phase 2
Completed NCT03319641 - PSMA-PET Imaging for Advanced ACC/SDC N/A
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT05483374 - The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
Completed NCT04291300 - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients Phase 2
Active, not recruiting NCT03172624 - Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Phase 2
Completed NCT00509002 - Iressa Study in Patients With Salivary Gland Cancer Phase 2
Active, not recruiting NCT05008237 - Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study Phase 2
Recruiting NCT03360890 - Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Phase 2
Not yet recruiting NCT05898373 - Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC Phase 1/Phase 2
Active, not recruiting NCT02069730 - A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes N/A
Recruiting NCT04209660 - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Phase 2
Completed NCT01344356 - Stereotactic Body Radiotherapy for Head and Neck Tumors Phase 4
Completed NCT03602079 - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Phase 1/Phase 2